TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8904367

Group type: EXPERIMENTAL
Intervention: Wearing hats and masks in ultraclean airflow theatres
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wearing balloon-cotton clothing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not wearing hats or masks in ultraclean airflow theatres
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wearing a hat but no mask in ultraclean airflow theatres
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wearing a mask but no hat in ultraclean airflow theatres
Number of subjects: 0

Group type: COMPARATOR
Intervention: Theoretical bacterial inoculum in conventional theatres or ultraclean theatres without hat or mask or wearing balloon-cotton clothing
Number of subjects: 0
Study: 2032513

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7137540

Group type: EXPERIMENTAL
Intervention: 1 mg/kg bupivacaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: 4 mg/kg prilocaine
Number of subjects: 20
Study: 31529008

Group type: EXPERIMENTAL
Intervention: Vaginal mesh hysteropexy
Number of subjects: 183

Group type: COMPARATOR
Intervention: Vaginal hysterectomy with uterosacral ligament suspension
Number of subjects: 183
Study: 28336284

Group type: EXPERIMENTAL
Intervention: Food supplementation with carotenoids (5mg of Lutein and 1mg of Zeaxanthin)
Number of subjects: 126

Group type: COMPARATOR
Intervention: No carotenoid supplementation (control group)
Number of subjects: 126
Study: 27485297

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (225 min/week) in ALPHA trial
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (300 min/week) in BETA trial
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (150 min/week) in BETA trial
Number of subjects: 720

Group type: COMPARATOR
Intervention: Control group (no activity) in ALPHA trial
Number of subjects: 720

Group type: COMPARATOR
Intervention: Control group (no activity) in BETA trial
Number of subjects: 720
Study: 24665578

Group type: EXPERIMENTAL
Intervention: Histamine concentrations of 1 mg/mL
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Histamine concentrations of less than 2 mg/mL
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Histamine concentrations
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Exercise-induced stress test
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Histamine bronchial provocation test
Number of subjects: 160
Study: 22926408

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (100-μg bolus)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 60
Study: 19817958

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) with artesunate
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo with artesunate
Number of subjects: 74
Study: 17332612

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/d)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 15657908

Group type: EXPERIMENTAL
Intervention: Combination of MRSI and MRI data
Number of subjects: 24

Group type: COMPARATOR
Intervention: MRSI data alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Addition of water intensities to the data set
Number of subjects: 24
Study: 11888968

Group type: EXPERIMENTAL
Intervention: Water seal
Number of subjects: 68

Group type: COMPARATOR
Intervention: Suction
Number of subjects: 68
Study: 9468365

Group type: EXPERIMENTAL
Intervention: Ritonavir, lamivudine, and zidovudine (triple combination treatment)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Ritonavir monotherapy (initial treatment before adding lamivudine and zidovudine)
Number of subjects: 33
Study: 8521898

Group type: EXPERIMENTAL
Intervention: Intravenous thyrotropin-releasing hormone (TRH) 200 micrograms
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 16
Study: 2222550

Group type: EXPERIMENTAL
Intervention: Controlled release propranolol (160 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional propranolol tablet (80 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Controlled release propranolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional propranolol tablet
Number of subjects: 12
Study: 7013310

Group type: EXPERIMENTAL
Intervention: Verrumal® (salicylic acid-containing product on a fluorouracil basis)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (without fluorouracil and without salicylic acid)
Number of subjects: 60
Study: 31580129

Group type: EXPERIMENTAL
Intervention: Intervention group received patients' mean ratings of their own health states before providing valuations.
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group received patients' mean ratings of their own health states after providing valuations.
Number of subjects: 155
Study: 29882696

Group type: EXPERIMENTAL
Intervention: Propofol post-conditioning (Cp 1.2 µg/mL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sevoflurane (0.5-2%)
Number of subjects: 60
Study: 29098740

Group type: EXPERIMENTAL
Intervention: Noncontact low-frequency ultrasound (NLFU) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 0
Study: 25880911

Group type: EXPERIMENTAL
Intervention: Goal-setting (GS)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Goal-setting with mentoring (GM)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (IC)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Goal-setting (GS) and Goal-setting with mentoring (GM) combined
Number of subjects: 75
Study: 23760223

Group type: EXPERIMENTAL
Intervention: Transpalpebral electrotherapy (n = 12), applied for 5 consecutive days with two sessions per day, each session including 8 spots (40 sec/spot) around the eye globe, current applied varied between 150 and 220 μA.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (n = 10).
Number of subjects: 22
Study: 21900084

Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 1761

Group type: COMPARATOR
Intervention: Defibrillator-only
Number of subjects: 1761
Study: 19593208

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 217

Group type: COMPARATOR
Intervention: CYP2C9*1*3
Number of subjects: 217

Group type: COMPARATOR
Intervention: CYP2C9*3
Number of subjects: 217
Study: 20209127

Group type: EXPERIMENTAL
Intervention: Positive framing over 10 years (the number escaping CVD per 1000)
Number of subjects: 1528

Group type: EXPERIMENTAL
Intervention: Negative framing over 10 years (the number that will have CVD)
Number of subjects: 1528

Group type: EXPERIMENTAL
Intervention: Negative framing per year over 10 years
Number of subjects: 1528

Group type: EXPERIMENTAL
Intervention: All presentations shown to participants
Number of subjects: 1528
Study: 15694559

Group type: EXPERIMENTAL
Intervention: Tiagabine b.i.d. (twice daily)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Tiagabine t.i.d. (three times daily)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Tiagabine b.i.d.
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Tiagabine t.i.d.
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Tiagabine b.i.d. and t.i.d.
Number of subjects: 243
Study: 12413995

Group type: EXPERIMENTAL
Intervention: Minimal-stimulation regimen (clomiphene citrate and gonadotropins)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard long GnRH agonist (GnRH-a)-gonadotropin stimulation
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Minimal-stimulation regimen with ganirelix
Number of subjects: 55
Study: 9856877

Group type: EXPERIMENTAL
Intervention: Epsilon‐aminocaproic acid (EACA) 100 mg/kg at cannulation followed by 25 mg/kg/h for 72 hours
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Epsilon‐aminocaproic acid (EACA)
Number of subjects: 29
Study: 7601182

Group type: EXPERIMENTAL
Intervention: Orchiectomy plus nilutamide (anandron)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Orchiectomy plus placebo
Number of subjects: 0
Study: 2146067

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of isophane (NPH) insulin
Number of subjects: 7

Group type: COMPARATOR
Intervention: Subcutaneous injection of isophane (NPH) insulin
Number of subjects: 7
Study: 147656

Group type: EXPERIMENTAL
Intervention: Oral contraceptive containing cyproterone acetate
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Oral contraceptive containing d-norgestrel
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (without hormonal medication)
Number of subjects: 3
Study: 12469457

Group type: EXPERIMENTAL
Intervention: Uninterrupted enteral nutrition (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Parenteral nutritional support (Group B)
Number of subjects: 40
Study: 31085131

Group type: EXPERIMENTAL
Intervention: High galectin-3 and low HDL-C
Number of subjects: 2970
Study: 30267385

Group type: EXPERIMENTAL
Intervention: Opicinumab (anti-LINGO-1; BIIB033)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 27165652

Group type: EXPERIMENTAL
Intervention: Physical activity and fall prevention intervention (30 groups) involving written information, fall risk assessment and prevention advice, a pedometer-based physical activity tracker, and telephone-based health coaching.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy eating intervention (30 groups) involving written information and telephone-based dietary coaching.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Physical activity and fall prevention intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy eating intervention
Number of subjects: 60
Study: 24877155

Group type: EXPERIMENTAL
Intervention: Corticocancellous bone block allograft (test group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Autologous bone block from chin area (control group)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both procedures (test and control)
Number of subjects: 16
Study: 23327028

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine‐‐fentanyl
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nalbuphine‐‐propofol
Number of subjects: 60
Study: 19741029

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) intervention (n = 21)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Routine care condition (n = 20)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) intervention
Number of subjects: 41
Study: 19808268

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 5010
Study: 15667429

Group type: EXPERIMENTAL
Intervention: Olanzapine (mean dosage 16.2 +/- 4.8 mg/day)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Clozapine (mean dosage 209 +/- 91 mg/day)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 114
Study: 11907310

Group type: EXPERIMENTAL
Intervention: Visible light cure (Triad VLC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Autopolymerizing (Orthoresin)
Number of subjects: 50
Study: 9934940

Group type: EXPERIMENTAL
Intervention: Intranasal vasopressin (20 IU before bedtime and after awakening)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 8748052

Group type: EXPERIMENTAL
Intervention: Individualized aerobic training at ventilatory threshold for 3 months
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (9 asthmatic children)
Number of subjects: 9
Study: 2189869

Group type: EXPERIMENTAL
Intervention: Alprazolam treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 10
Study: 619934

Group type: EXPERIMENTAL
Intervention: Controlled release tablet containing 300 mg of papaverine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capsule containing 300 mg of papaverine hydrochloride
Number of subjects: 0
Study: 30531418

Group type: EXPERIMENTAL
Intervention: Plyo Press Power Quotient (3PQ) test using a horizontal leg press equipped with a force plate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1RM strength testing for 1 and 2 legs and countermovement vertical jump
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2-leg jump tests at 30, 40, 50, and 60% of 1RM for 20 and 30 seconds
Number of subjects: 30
Study: 29464487

Group type: EXPERIMENTAL
Intervention: Myopic monovision group (dominant eye -2.75D, nondominant eye -1.75D)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Myopic monovision group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-monovision group (bilateral -2.75D)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 26744025

Group type: EXPERIMENTAL
Intervention: liraglutide 3.0 mg
Number of subjects: 5325

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 5325
Study: 23130938

Group type: EXPERIMENTAL
Intervention: SOLITAIRE™ Flow Restoration device
Number of subjects: 0

Group type: COMPARATOR
Intervention: MERCI Retrieval System®
Number of subjects: 0
Study: 23173830

Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy (PST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced treatment-as-usual (E-TAU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PST and CBT
Number of subjects: 0
Study: 20152559

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 1548

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 1548
Study: 17722957

Group type: EXPERIMENTAL
Intervention: 3-week cycles of intravenous (IV) docetaxel plus cisplatin and fluorouracil (5-fluorouracil)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Cisplatin plus IV fluorouracil (4-week cycles)
Number of subjects: 445
Study: 16252573

Group type: EXPERIMENTAL
Intervention: Rivastigmine 3‐6 mg twice daily for 20 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no rivastigmine)
Number of subjects: 38
Study: 11697709

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (0.3 g/kg in a 4-week cycle until the 28th to 32nd week of gestation), aspirin (100 mg/d), and certoparin (3,000 anti-Xa U/d)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard therapy (aspirin and low‐molecular‐weight heparin)
Number of subjects: 66
Study: 9918642

Group type: EXPERIMENTAL
Intervention: Bionators
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Headgears
Number of subjects: 168

Group type: COMPARATOR
Intervention: Both Bionators and Headgears
Number of subjects: 168
Study: 7998586

Group type: EXPERIMENTAL
Intervention: rilmenidine 1-2 mg/day (n = 46)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCZ) 25-50 mg/day (n = 42)
Number of subjects: 88
Study: 3056208

Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone (1%) at induction of anaesthesia
Number of subjects: 243

Group type: COMPARATOR
Intervention: Povidone iodine sprayed into the wound at the completion of surgery
Number of subjects: 243
Study: 29893942

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 108

Group type: COMPARATOR
Intervention: Sham electroacupuncture
Number of subjects: 108

Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 108

Group type: COMPARATOR
Intervention: Education alone (after electroacupuncture during follow-up)
Number of subjects: 108
Study: 28430748

Group type: EXPERIMENTAL
Intervention: Vero cell‐derived inactivated JE virus vaccine (IXIARO), 0.25 mL for <3 years and 0.5 mL for ≥3 years, administered 28 days apart
Number of subjects: 496
Study: 25881753

Group type: EXPERIMENTAL
Intervention: Pomaglumetad methionil 400 mg
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 86
Study: 22843041

Group type: EXPERIMENTAL
Intervention: Sand training surface
Number of subjects: 10

Group type: COMPARATOR
Intervention: Grass training surface
Number of subjects: 10
Study: 21515164

Group type: EXPERIMENTAL
Intervention: Performance-based payment (P4P) for health-care providers
Number of subjects: 2158

Group type: COMPARATOR
Intervention: Traditional input-based funding
Number of subjects: 2158
Study: 20027348

Group type: EXPERIMENTAL
Intervention: Anaferon (pediatric formulation) as a component of complex therapy
Number of subjects: 0
Study: 16495392

Group type: EXPERIMENTAL
Intervention: Glucosamine 1500 mg daily
Number of subjects: 1583

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate 1200 mg daily
Number of subjects: 1583

Group type: EXPERIMENTAL
Intervention: Combined glucosamine and chondroitin sulfate
Number of subjects: 1583

Group type: COMPARATOR
Intervention: Celecoxib 200 mg daily
Number of subjects: 1583

Group type: EXPERIMENTAL
Intervention: Combined therapy (glucosamine and chondroitin sulfate) in moderate-to-severe pain
Number of subjects: 1583
Study: 15527670

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 401

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 401
Study: 11134125

Group type: EXPERIMENTAL
Intervention: Estradiol therapy (transdermal or oral)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 27
Study: 9481970

Group type: EXPERIMENTAL
Intervention: 1.0MAC with block analgesia
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 1.3MAC with block analgesia
Number of subjects: 28

Group type: COMPARATOR
Intervention: 1.3MAC without block analgesia
Number of subjects: 28

Group type: COMPARATOR
Intervention: 1.6MAC without block analgesia
Number of subjects: 28
Study: 7885579

Group type: EXPERIMENTAL
Intervention: Walking with hand movements
Number of subjects: 6

Group type: COMPARATOR
Intervention: Walking with no hand movements
Number of subjects: 6

Group type: COMPARATOR
Intervention: Age-matched control patients
Number of subjects: 6
Study: 3351823

Group type: EXPERIMENTAL
Intervention: Cefonicid (1 g preoperative dose)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cefoxitin (2 g preoperative and postoperative for a total of four doses)
Number of subjects: 100
Study: 29458053

Group type: EXPERIMENTAL
Intervention: Whole grain diet (WG diet)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Refined grain diet (RG diet)
Number of subjects: 80
Study: 27203820

Group type: EXPERIMENTAL
Intervention: Very-low calorie diet
Number of subjects: 64
Study: 25784723

Group type: EXPERIMENTAL
Intervention: Exercise group (n=28)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 48
Study: 23183881

Group type: EXPERIMENTAL
Intervention: Lopinavir (LPV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lamivudine (3TC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV)
Number of subjects: 0
Study: 21122270

Group type: EXPERIMENTAL
Intervention: Infliximab treatment for 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (age- and weight-matched men)
Number of subjects: 30
Study: 18230018

Group type: EXPERIMENTAL
Intervention: Hypothetical cardiac risk information with a focus on relative differences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypothetical cardiac risk information with a focus on absolute differences
Number of subjects: 0
Study: 16732903

Group type: EXPERIMENTAL
Intervention: PegIntron (1.0 microg/kg body weight, SC, once a week)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Intron A (3 MIU SC, three times a week)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: PegIntron
Number of subjects: 230

Group type: COMPARATOR
Intervention: Intron A
Number of subjects: 230
Study: 12079904

Group type: EXPERIMENTAL
Intervention: Recombinant DNA hepatitis B vaccine (3 doses: 2nd and 3rd doses at 1 and 6 months)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Recombinant DNA hepatitis B vaccine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 44
Study: 9460778

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (four days/week; 30-40 minutes/session)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Aerobic exercise with physician recommendation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 24
Study: 8589769

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 2162877

Group type: EXPERIMENTAL
Intervention: Thiazide diuretic (Moduretic; Merck Sharp & Dohme)
Number of subjects: 2630

Group type: EXPERIMENTAL
Intervention: Beta-blocking agent (atenolol)
Number of subjects: 2630

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2630
Study: 418433

Group type: EXPERIMENTAL
Intervention: PRL-8-53
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6177804

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) titer greater than 10 units in acute-phase sera
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Antiviral activity in acute-phase sera
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Convalescent-phase sera
Number of subjects: 57
Study: 31517756

Group type: EXPERIMENTAL
Intervention: MINDBODYSTRONG Program
Number of subjects: 89

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 89
Study: 29110922

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil + Best Supportive Care (BSC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best Supportive Care (BSC) alone
Number of subjects: 0
Study: 27007989

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 50

Group type: COMPARATOR
Intervention: Calcium Carbonate
Number of subjects: 50
Study: 24726204

Group type: EXPERIMENTAL
Intervention: Clinical Pharmacist‐Led Guidance Teams (CPGTs)
Number of subjects: 542

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 542
Study: 23225555

Group type: EXPERIMENTAL
Intervention: Transanal real-time elastography (RTE)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional B-mode/color Doppler EUS
Number of subjects: 90
Study: 21139110

Group type: EXPERIMENTAL
Intervention: Integrated care (IC)
Number of subjects: 943

Group type: COMPARATOR
Intervention: Referral to Veterans Affairs smoking cessation clinics (SCC)
Number of subjects: 943